Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection
Authors:
Open Access
- 2 January 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (1) , 51-64
Abstract
Oncolytic virus (OV) therapy represents a promising approach currently undergoing (pre)-clinical testing for several cancers. Until recently, it was thought that the tropism of oncolytic viruses was restricted to epithelial cancer cells unless they were modified to target additional cell types. It has now become evident that some OVs possess a natural ability to target cancer-associated fibroblasts (CAFs). CAFs are strongly highlighted in supporting cancer progression and impeding anti-cancer therapeutics. Therefore, targeting CAFs in addition to tumor cells could enhance therapy efficacy. To date, the molecular determinants of tumor cell permissiveness to OV therapy have been thoroughly investigated. The recent notion that CAFs could also be a target for OVs highlights the importance of a comparable understanding of what makes CAFs permissive to OVs. This review explores the various molecular pathways and molecules that may affect the susceptibility of CAFs to OV infection and lysis. We discuss the potential impact of virus entry receptors, microRNAs, Ras and PI3K/AKT signaling, p53 status and type I interferon signaling. Further scrutinizing the factors that influence sensitivity of CAFs to OVs can help to identify targets for therapy optimization, especially in tumors with a high abundance of CAFs.Keywords
Funding Information
- Overleven met Alvleesklierkanker (SOAK 21.02)
- Dutch Research Council
This publication has 149 references indexed in Scilit:
- Extracellular matrix cancer‐associated fibroblasts promote stromal fibrosis and immune exclusion in triple‐negative breast cancerThe Journal of Pathology, 2025
- IFNγ and TNFα drive an inflammatory secretion profile in cancer‐associated fibroblasts from human non‐small cell lung cancerFEBS Letters, 2025
- Preclinical evaluation of the gorilla‐derived HAdV‐B AdV‐lumc007 oncolytic adenovirus ‘GoraVir’ for the treatment of pancreatic ductal adenocarcinomaMolecular Oncology, 2024
- Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibodyCancer Immunology, Immunotherapy, 2023
- Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectivesCancer Communications, 2022
- Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activityCellular and Molecular Life Sciences, 2020
- MiR‐26b is down‐regulated in carcinoma‐associated fibroblasts from ER‐positive breast cancers leading to enhanced cell migration and invasionThe Journal of Pathology, 2013
- Adenovirus receptors: implications for tropism, treatment and targetingReviews in Medical Virology, 2009
- Genomic Instability Within Tumor Stroma and Clinicopathological Characteristics of Sporadic Primary Invasive Breast CarcinomaJAMA, 2007
- Three Classes of Cell Surface Receptors for Alphaherpesvirus EntryVirology, 2000